Glutamic acid

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
Wednesday, April 3, 2024
Discovery, Epilepsy, GABAB, Senior, Glutamic acid, Dyskinesia, Glutamate (neurotransmitter), Drug discovery, Partnership, TBI, SIX, Chronic cough, NAM, CHF5, Therapy, DSM-IV codes, Janssen, Safety, ADX71149, Allosteric regulation, Janssen Pharmaceuticals, Dipraglurant, Research fellow, PAM, Pharmaceutical industry

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.

Key Points: 
  • With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.
  • In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix.
  • “The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.
  • To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix.

Addex to Present at Biotech Showcase™ 2024

Retrieved on: 
Friday, January 5, 2024
Glutamic acid, Protein, Drug discovery, DSM-IV codes, PAM, Janssen Pharmaceuticals, Biotechnology, Epilepsy, Depression, NAM, ADX71149, Allosteric regulation, SIX Swiss Exchange, Psychosis, Glutamate (neurotransmitter), Therapy, GABAB, Schizophrenia, Chronic cough, American depositary receipt

For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .

Key Points: 
  • For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .
  • Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders.
  • Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Retrieved on: 
Tuesday, November 14, 2023
ClinicalTrials.gov, Safety, Johnson & Johnson, Therapy, Janssen Pharmaceuticals, Cohort, Patient, ADX71149, Part, PAM, Pharmacokinetics, Levetiracetam, Trial of the century, Part 1, IRC, Seizure, Janssen, SIX, Glutamic acid, Part Two, Pharmaceutical industry

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, November 14, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the last patient has been randomized in Cohort 2 of the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study.
  • The primary efficacy endpoint of this study is time to baseline monthly seizure count.
  • The multi-center Phase 2 study has been designed to assess the efficacy, safety, tolerability, and pharmacokinetics of adjunctive ADX71149 administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.
  • In addition, patients who complete Part 1 and/or Part 2 of the study have the option to continue treatment in the open-label extension part of the study, which evaluates the long-term efficacy and safety of ADX71149.

Styrene Butadiene (SB) Latex Market to grow by USD 1.49 billion from 2023 to 2028 | Asahi Kasei Corp., BASF SE, Dow Chemical Co., and more among key companies- Technavio

Retrieved on: 
Thursday, November 30, 2023
Adhesive, BASF SE, Lanxess, Paper, Methanol, RPM International, LG Chem, USD, BASF, Glutamic acid, Geography, Growth, SE, Free, Synthetic rubber, Speciality chemicals

NEW YORK , Nov. 29, 2023 /PRNewswire/ -- The styrene butadiene (SB) latex market is expected to grow by USD 1.49 billion from 2023 to 2028.

Key Points: 
  • NEW YORK , Nov. 29, 2023 /PRNewswire/ -- The styrene butadiene (SB) latex market is expected to grow by USD 1.49 billion from 2023 to 2028.
  • Growing demand for SB latex from APAC and Europe is notably driving the styrene butadiene (SB) latex market.
  • Styrene Butadiene (SB) Latex Market 2024-2028: Company Analysis
    Asahi Kasei Corp - The company offers SB Latex products for Paper coating, adhesives, paints, etc.
  • View the Free PDF Sample Report
    Styrene Butadiene (SB) Latex Market 2024-2028: Key Highlights
    The glutamic acid market size is estimated to grow by USD 5.08 billion at a CAGR of 7.99% between 2023 and 2028.

Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

Retrieved on: 
Wednesday, September 20, 2023
Cognition, Epilepsy, ADX71149, LR, NAM, Glutamic acid, Therapy, SIX, IND, Pharmaceutical industry, Eurostar

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, September 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has led a consortium which has been awarded a €4 million Eurostars grant to support its metabotropic glutamate 2 (mGlu2) receptor negative allosteric modulator (NAM) program for mild neurocognitive disorder (mNCD).
  • The project, named COGNI+, has been awarded the grant to deliver clinical candidates ready for IND enabling studies.
  • The consortium includes Naason Science (South Korea), BioAxis Research (Netherlands), Pharmidex Pharmaceutical Services (UK) and Stichting Radboud Universiteit (Netherlands).
  • “Our mGlu2 NAM program has made significant advances in our understanding of the function of mGlu2 receptors and their role played in neuronal processes involved in cognition.

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

Retrieved on: 
Tuesday, September 5, 2023
Part 1, Epilepsy, Maintenance, IRC, Levetiracetam, PAM, ADX71149, Cohort, LR, Pharmacokinetics, Part, Trial of the century, Janssen Pharmaceuticals, Glutamic acid, Patient, Part Two, Seizure, Johnson & Johnson, Therapy, SIX, ClinicalTrials.gov, Safety, Pharmaceutical industry

Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohorts 1 and Cohort 2 are anticipated for the second quarter of 2024.

Key Points: 
  • Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohorts 1 and Cohort 2 are anticipated for the second quarter of 2024.
  • The primary efficacy endpoint of this study is time to baseline monthly seizure count.
  • Collaboration partner Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, is responsible for the clinical development of ADX71149.
  • The primary objective of the study is to evaluate the efficacy of ADX71149 in combination with levetiracetam or brivaracetam using a time to baseline seizure count endpoint.

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Retrieved on: 
Monday, July 24, 2023
Epilepsy, Scripps Research, Nicotine, PAM, ADX71149, Oxycodone, LR, Research, Opioid, Trial of the century, Discovery, Glutamic acid, Cocaine, Motivation, Drug, Rat, SCM, PAMS, SIX, SD, Biology, Pharmaceutical industry, Neuropharmacology

The data were published in Neuropharmacology by Addex and The Scripps Research Institute.

Key Points: 
  • The data were published in Neuropharmacology by Addex and The Scripps Research Institute.
  • “In the United States, opioid abuse and overdose have reached epidemic proportions, with oxycodone being the most abused prescription opioid.
  • In previous research, this approach has successfully been used in nicotine, cocaine and alcohol models,” said Dr. Robert Lütjens, Head of Discovery – Biology at Addex.
  • “Demonstrating the wide potential of mGlu2 PAMs, an Addex discovered drug candidate, ADX71149, is being evaluated in a phase 2 clinical study as a potential treatment for epilepsy by our partner Janssen.”

Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

Retrieved on: 
Wednesday, May 10, 2023
Part 1, Seizure, Maintenance, IRC, Levetiracetam, PAM, ADX71149, LR, Pharmacokinetics, Brain, Part, Metcalf, Trial of the century, Janssen Pharmaceuticals, Glutamic acid, Patient, Part Two, Johnson & Johnson, Therapy, SIX, ClinicalTrials.gov, Safety, Pharmaceutical industry, Epilepsy

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, May 10, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study has been recommended to continue by an Independent Interim Review Committee (IRC) following review of unblinded data from Part 1 of patient Cohort 1.
  • The clinical study is being conducted by Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • ADX71149 was described in the Eilat 15 conference summary review as a promising novel approach currently in development (Bialer et al., 2020.
  • Proof of concept data with ADX71149 and other mGlu2 PAMs in animal models of epilepsy have been published in peer-reviewed journals (Metcalf et al., 2017 and 2018.

Outlook on the Enzyme Global Market to 2035: Players Include Adisseo, AB Enzymes, Amano Enzyme, BASF and Codexis - ResearchAndMarkets.com

Retrieved on: 
Friday, February 24, 2023
Health, Other Health, Diabetes, Glutamic acid, Food, ICMR, Protein, Cancer, Evaluation, Chronic pain, Indian Council of Medical Research, Sensation, Medical research, Public Health Foundation of India, Institute for Health Metrics and Evaluation, GMO, Pulse, Enzyme, Growth, Sciatica, MSG, Arthritis, Incidence, Type 2 diabetes, Prevalence, Fine chemical

Moreover, the high demand of enzymes in food and beverage industry is a key contributing factor for the market growth.

Key Points: 
  • Moreover, the high demand of enzymes in food and beverage industry is a key contributing factor for the market growth.
  • Moreover, the rising prevalence and incidence rates of chronic illnesses across the world is driving the growth of the enzyme at a substantial rate.
  • On the other hand, the immense concern related to the handling and safety issues of enzymes is constricting the market growth.
  • The global enzyme market is segmented into type, source, reaction type, and application.

Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries

Retrieved on: 
Monday, February 6, 2023
Research, Medical cannabis, Neuron, Excitotoxicity, Parkinson's disease, OTC, Glutamic acid, Cannabidiol, Central nervous system, Brain damage, Cerebral cortex, Patient, SAN, El Siglo, Medical Marijuana, Inc., THC, Mortality, Death, Pharmaceutical industry, Vaccine, CBD

SAN DIEGO, CA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary HempMeds® recently took part in a collaboration on a study to demonstrate the effectiveness of hemp-based cannabidiol (CBD) in the treatment of Parkinson's Disease.  The Company is also collaborating with the Center for Research and Advanced Studies of Neurological Diseases at the Siglo XXI National Medical Center, on a preclinical study in an animal model that demonstrated the ability to decrease extracellular glutamate levels that can lead to traumatic brain injuries.

Key Points: 
  • The Company is also collaborating with the Center for Research and Advanced Studies of Neurological Diseases at the Siglo XXI National Medical Center, on a preclinical study in an animal model that demonstrated the ability to decrease extracellular glutamate levels that can lead to traumatic brain injuries.
  • In this study, it was also shown that the application of CBD helps sensorimotor improvement,” Dr. Rocha stated.
  • Dr. Rocha added: “The results obtained in this study help to understand how the oral application of cannabidiol reduces excitotoxicity caused by long-term traumatic brain injuries and facilitates functional recovery.
  • HempMeds' commitment is to free access around the globe enabling people worldwide everyday to obtain the health benefits of cannabis-based products in an easy way.